Resultados de la búsqueda 61-70 of 3340 for Agmatine Sulfate

1. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

2. Hematología - Ensayos clínicos - Mayo Clinic

   Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

3. Hematología - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to evaluate the safety and tolerability, identify dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD and ...

4. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

5. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with ...

6. Hematología - Ensayos clínicos - Mayo Clinic

   The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill ...

7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...